Mastering the risk of HLA antibodies in kidney transplantation: An algorithm based on pretransplant single-antigen flow bead techniques

American Journal of Transplantation

Volumn 11, Issue 8, 2011, Pages 1592-1598

  Lefaucheur, C ^a   Antoine, C ^a,b   Suberbielle, C ^a   Glotz, D ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Direction médicale et scientifique Agence de la biomédecine   (France)

Author keywords

alllosensitization; Allocation; deceased donor kidneys; waiting list

Indexed keywords

HLA ANTIBODY;

ADULT; AGED; ALGORITHM; ANALYTIC METHOD; ANTIBODY DETECTION; CLINICAL PROTOCOL; CONTROLLED STUDY; DESENSITIZATION; FEMALE; GRAFT SURVIVAL; HLA TYPING; HOSPITAL ADMISSION; HUMAN; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIMULATION; SINGLE ANTIGEN FLOW BEAD;

ALGORITHMS; ANTIBODIES; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION;

EID: 79961022403     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03560.x     Document Type: Review

References (30)

1. Gebel HM, Bray RA, Nickerson P,. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488-1500. (Pubitemid 37541506)
2. Lefaucheur C, Suberbielle-Boissel C, et al,. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324-331.
3. Patel AM, Pancoska C, Mulgaonkar S, Weng FL,. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7: 2371-2377. (Pubitemid 47347867)
4. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681-1688.
5. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
6. Gloor J, Cosio F, Lager DJ, Stegall MD,. The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Am J Transplant 2008; 8: 1367-1373. (Pubitemid 351989489)
7. Gloor JM, Cosio FG, Rea DJ, et al,. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841-1847. (Pubitemid 44024955)
8. Haas M, Montgomery RA, Segev DL, et al,. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576-585. (Pubitemid 46376440)
9. Loupy A, Suberbielle-Boissel C, Hill GS, et al,. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
10. Mauiyyedi S, Pelle PD, Saidman S, et al,. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582. (Pubitemid 32180027)
11. Regele H, Bohmig GA, Habicht A, et al,. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380. (Pubitemid 34925248)
12. Cecka JM,. Calculated PRA (CPRA): The new measure of sensitization for transplant candidates. Am J Transplant 2010; 10: 26-29.
13. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS,. Calculated PRA: Initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011; 11: 719-724.
14. Morath C, Beimler J, Opelz G, et al,. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 2010; 90: 645-653.
15. Vo AA, Lukovsky M, Toyoda M, et al,. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251. (Pubitemid 352008439)
16. Jacquelinet C, Audry B, Golbreich C, et al,. Changing kidney allocation policy in France: The value of simulation. AMIA Annu Symp Proc 2006: 374-378.
17. Activity Report of Graft. Agence de la Biomédecine. Available at. Accessed December 19, 2008.
18. Zachary AA, Montgomery RA, Leffell MS,. Defining unacceptable HLA antigens. Curr Opin Organ Transplant 2008; 13: 405-410.
19. Zachary AA, Sholander JT, Houp JA, Leffell MS,. Using real data for a virtual crossmatch. Hum Immunol 2009; 70: 574-579.
20. Vaidya S,. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008; 85: 1046-1050. (Pubitemid 351543170)
21. Nikaein A, Cherikh W, Nelson K, et al,. Organ procurement and transplantation network/united network for organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients. Transplantation 2009; 87: 557-562.
22. Tambur AR, Ramon DS, Kaufman DB, et al,. Perception versus reality?: Virtual crossmatch-how to overcome some of the technical and logistic limitations. Am J Transplant 2009; 9: 1886-1893.
23. Tambur AR, Leventhal JR, Friedewald JJ, Ramon DS,. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010; 90: 1117-1124.
24. Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II,. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. Transplantation 2004; 78: 190-193.
25. Akalin E, Dinavahi R, Friedlander R, et al,. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3: 1160-1167.
26. Anglicheau D, Loupy A, Suberbielle C, et al,. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: A pilot study. Am J Transplant 2007; 7: 1185-1192. (Pubitemid 46643104)
27. Bachler K, Amico P, Honger G, et al,. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010; 10: 1254-1262.
28. Loupy A, Suberbielle-Boissel C, Zuber J, et al,. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation 2010; 89: 1403-1410.
29. Stegall M, Diwan T, Burns J,. Prevention of acute humoral rejection with C5 inhibition. Am J Transplant 2009; 9 (Suppl 2): 241-242 (Abstract 178).
30. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S,. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351. (Pubitemid 43382170)